Robin (Rob) B. Hutchison, Chairman & CEO
|
Mr. Hutchison, the founder of biOasis Technologies Inc., is also the founder of several companies including eCharge Corporation (“eCharge”) of Seattle, Washington, which specializes in alternative payment methods for the Internet. He served as the President and Chief Technical Officer of eCharge and played an integral role in raising over US$90 million in private funding. Mr. Hutchison pioneered and holds the patents on unique digital certificate technology, which enabled eCharge to provide secure Internet commerce transactions. Mr. Hutchison retired from eCharge in 2002 but still remains as the key Scientific Advisor to the company.
|
|
Prior to co-founding eCharge, Mr. Hutchison was the President of Canada-based SNI Corporation, which specializes in the integration of SUN Microsystems UNIX-based systems with the Internet and computer firewall security. He also served as the Western regional director of sales and operations for Everex Canada Inc.
Since then, he has assisted in the development of several start-ups and mature technology companies. Mr. Hutchison is a member of the Board of Directors of Golden Goliath Resources. |
| David Clark, Chief Financial Officer & Director |
Mr. Clark is a chartered accountant with more than 30 years experience in banking and a wide range of industries, including biotechnology, transaction automation and electronic payments, software, brewing, junior oil and gas, mineral exploration, real estate development, and environmental technologies. He has acted in senior roles in these companies, principally as a
|
|
director, President, Chief Financial Officer, or as senior financial or corporate finance consultant. Mr. Clark has managed taking companies public; mergers and acquisitions; and raising significant funds through public and private equity and/or debt. Clark’s banking experience comprises eight years with Security Pacific Bank Canada (now Bank of America Canada), most latterly in the position of Senior Vice-President and CFO.
|
| Dr. Wilfred Jefferies, Chair Scientific Board, Chairman of the Scientific Advisory Board |
Dr. Jefferies is a Professor and the Chairman of the SAB. He previously founded Synapse Technologies Inc., which was subsequently acquired by BioMarin Pharmaceuticals Inc. A world expert in identifying biomarkers of Alzheimer’s disease and in the delivery of drugs across the blood brain barrier, he holds no less than 20 issued patents. Jefferies is internationally recognized as a scientific leader and innovator and is the lead inventor of biOasis’ scientific technologies.
Dr. Jefferies holds a Bachelor of Science degree in Biochemistry from the University of Victoria and a Doctor of Philosophy degree from the Sir William Dunn School of Pathology at the University of Oxford. He is a Professor in the Michael Smith Laboratories and the Biomedical Research Centre as well as in the Departments of Medical Genetics, Microbiology and Immunology and Zoology at the University of British Columbia. Early in his career, Jefferies defined the role of iron in promoting cancer cell growth and was the first to define a pathway of iron acquisition by melanomas. These discoveries lead directly to methods for removing cancer cells from autologous bone marrow, a technology that is still in use today. Furthermore, he was instrumental in defining the receptor system for the passage of iron from the blood into the brain. This seminal discovery lead to the development of new drug delivery systems for the delivery of drugs into the brain. These studies are widely cited and have had an immense impact on understanding the biology of the blood brain barrier. His continued interest in iron transport to the brain led to the discovery of the first unique marker of reactive microglia associated with the senile plaques in Alzheimer's disease brains.
|
|
This remains the first and only marker of its kind that has been validated in double blind trials and that has been independently confirmed. His group recently demonstrated that this barrier is impaired in Alzheimer’s disease prior to disease onset and preceeds the appearance of plaques in the brain. These pioneering studies have again created the seed for another new area of scientific investigation that is being actively followed by the research community. This finding links Alzheimer's disease and stroke in a unique way and may form the basis for understanding at the cell and molecular level the modality of Alzheimer’s disease vaccines and methods to treat the disease.
His scientific studies have been published in the world’s most prestigious scientific journals including Nature, Proceedings of the National Academy of Science (USA), Nature Immunology, Journal of Experimental Medicine, EMBO Journal, Nature Biotechnology, FASEB Journal, Journal of Biological Chemistry, Nature Biotechnology, PLoS Pathogens and in many cancer related journals,including Cancer Research and the International Journal of Cancer Research. His discoveries have been described in the popular press in such publications as the Readers Digest, Popular Mechanics and newspapers such as the New York Times, the London Telegraph, the Washington Post and the Globe and Mail. Jefferies is a recipient of a University Killam Faculty Research Fellowship and has received numerous other fellowships and scholarships throughout his career. Jefferies was awarded the Microcirculatory Society's Wiederhelm Award in 2008 for his pioneering studies on the deterioration of the Blood Brain Barrier in Alzheimer’s disease. |
Mr. (“Mark”) Godsy, Strategic Advisor
|
Mark is a very successful and experienced entrepreneur working in the area of corporate development and venture capital whom is the co-founded of ID Biomedical which was eventually sold to GSK for US$1.4 billion and was the business co-founder of Angiotech Pharmaceuticals,
|
|
another very successful Canadian biotechnology company. Mark is a graduate of the University of British Columbia and received his law degree from McGill University.
|
| Page 1 of 2 Next >> |
|
